Company news
Moberg Pharma Ab (OMXSTO:MOB) news
Moberg Pharma Ab news releases on 6ix. Latest, Oct 5, 2026: New analyses on terbinafine susceptibility and MOB-015 published in Journal of Fungi
Press releases & updates
New analyses on terbinafine susceptibility and MOB-015 published in Journal of Fungi
October 5, 2026
Moberg Pharma's Terclara[® ](MOB-015) launched in Israel
September 23, 2026
M O B A Network : Proposal for an up to SEK 11.3 million directed share issue in M.O.B.A. to secure obligations under its outstanding bonds
September 14, 2026
Moberg Pharma strengthens organization ahead of European launch
August 11, 2026
New number of shares and votes in Moberg Pharma AB (publ)
June 30, 2026
Moberg Pharma reports progress on commercial launch preparations
June 15, 2026
Notice of Annual General Meeting in Moberg Pharma AB (publ)
April 17, 2026
Moberg Pharma and Karo Healthcare enter into an exclusive license agreement for MOB-015/Terclara in Europe, expanding access and growth potential
November 5, 2025
Karo Healthcare enters an exclusive license agreement with Moberg Pharma for MOB-015 in Europe
November 5, 2025